Hereditary angioedema: A current state-of-the-art review, II: Historical perspective of non-histamine-induced angioedema

Annals of Allergy, Asthma and Immunology

Volumn 100, Issue 1 SUPPL. 2, 2008, Pages

  Bernstein, I Leonard ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DX 88; HISTAMINE; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; METHYLTESTOSTERONE; PLASMIN; STANOZOLOL; TESTOSTERONE; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; BLOOD CLOTTING; CLINICAL RESEARCH; COMPLEMENT BLOOD LEVEL; CONFERENCE PAPER; DISEASE ASSOCIATION; DNA SEQUENCE; FAMILIAL DISEASE; FIBRINOLYSIS; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MEDLINE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

EID: 38049077825     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60579-0     Document Type: Conference Paper

References (65)

1. Donati M. De medica historia mirabile. Mantua Osana. 1586;VII:Capiii:304.
2. Arnoldsson H, Belin L, Hallberg L, et al. Hereditary periodic oedema. Acta Med Scand. 1967;181:115.
3. Graves RJ. Clinical Lectures on the Practice of Medicine. London, England: New Sydenham Society; 1884:531.
4. Dinkelacker E. Uber Akutes Oedem [inaugural dissertation]. Kiel, Germany: University of Kiel; 1882.
5. Quincke H. Über akutes umschriebenes Hautödem. Monatshefte Prakt Dermtol. 1882;1:129-131.
6. Straubring P. Über akutes (angioneurotisches) oedem. Ztschr Klin Med. 1885;9:381.
7. Osler W. Hereditary angioneurotic edema. Am J Med Sci. 1888;95:362-367.
8. Bulloch W. Angioneurotic oedema, the treasury of human inheritance. Eugenics. 1909;9:38.
9. Crowder JR, Crowder TR. Five generations of angioneurotic edema. Arch Intern Med. 1917;20:840.
10. Pillemer L, Ratnoff OD, Blum L, Lepow IH. The inactivation of complement and its components by plasmin. J Exp Med. 1953;97:573-589.
11. Lepow IH, Pillemer L, Ratnoff OD. The influence of calcium ions on the inactivation of human complement and its components by plasmin. J Exp Med. 1953;98:277-289.
12. Levine L. Inhibition of immune hemolysis by diisopropyl fluorophosphate. Biochim Biophys Acta. 1955;18:283-284.
13. Lepow IH, Ratnoff OD, Pillemer L. Elution of an esterase from antigen-antibody aggregates treated with human complement. Proc Soc Exp Biol Med. 1956;92:111-114.
14. Miles AA, Wilhelm DL. Enzyme-like globulins from serum reproducing the vascular phenomena of inflammation, I: an activable permeability factor and its inhibitor in guinea pig serum. Br J Exp Pathol. 1955;36:71-81.
15. Becker EL. Concerning the mechanism of complement action, I: inhibition of complement activity by diisopropylfluorophosphate. J Immunol. 1956;77:462-468.
16. Becker EL. Hypersensitivity. J Cell Comp Physiol.1957;50(suppl 1):303-325.
17. Ratnoff OD, Miles AA. The induction of permeability-increasing activity in human plasma by activated Hageman factor. Br J Exp Pathol. 1964;45:328-345.
18. Lepow IH, Ratnoff OD, Rosen FS, et al. Observations on a pro-esterase associated with partially purified first component of human complement (C'I). Proc Soc Exp Biol Med. 1956;92:32-37.
19. Webster ME, Ratnoff OD. Role of Hageman factor in the activation of vasodilator activity in human plasma. Nature. 1961;192:180-181.
20. Ratnoff OD, Davie EW. The purification of activated Hageman factor (activated factor XII). Biochemistry. 1962;1:967-975.
21. Ratnoff OD, Botti RE, Crum JD, et al. The activation of PTA (factor XI) and Hageman factor (factor XII). Thromb Diath Haemorrh Suppl. 1965;17:1-14.
22. Osihi S, Webster ME. Vascular permeability factors (PF/Nat and PF/Dil): their relationship to Hageman factor and the kallikrein-kinin system. Biochem Pharmacol. 1975;24;591-598.
23. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med. 1981;153:665-676.
24. Levy LR, Lepow IH. Assay and properties of serum inhibitor of C'1 esterase. Proc Soc Exp Biol Med. 1959;101:608-611.
25. Landerman NS, Webster ME, Becker EL, et al. Increased cutaneous response to diluted autologous serum in hereditary angio-edema. Lancet. 1960;2:1053.
26. Landerman NS, Webster ME, Becker EL, et al. Hereditary angioneurotic edema, II: deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy. 1962;33:330.
27. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema. Am J Med. 1963;35:37-43.
28. Donaldson VH, Ratnoff OD, Dias Da Silva W, Rosen FS. Permeability- increasing activity in hereditary angioneurotic edema plasma, II: mechanism of formation and partial characterization. J Clin Invest. 1969;48:642-653.
29. Strang CJ, Cholin S, Spragg J, et al. Angioedema induced by a peptide derived from complement component C2. J Exp Med. 1988;168:1685-1698.
30. Rosen FS, Charache P, Pensky J, et al. Hereditary angioneurotic edema: two genetic variants. Science. 1965;148:957-958.
31. Warin RP, Cunliffe WJ, Greaves MW, et al. Recurrent angioedema: familial and oestrogen-induced. Br J Dermatol. 1986;115:731-734.
32. Bork K, Barnstedt SE, Koch P, et al. Herditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213-217.
33. Binkley KE, Davis A III. Clinical, biochemical and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106:546-550.
34. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343:286-289.
35. Caldwell JR, Ruddy S, Schur PH, et al. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol. 1972;1:39-52.
36. Malbran A, Hammer CH, Frank MM, et al. Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J Allergy Clin Immunol. 1988;81:1199-1204.
37. Cicardi M, Bisiani G, Cugno M, et al. Autoimmune C1 inhibitor deficiency: report of eight patients. Am J Med. 1993;95:169-175.
38. Bibi-Triki T, Eclache V, Frilay Y, et al. Acquired C1 inhibitor deficiency associated with lymphoproliferative disorders: four cases. Rev Med Intern. 2004;25:667-672.
39. Sinclair D, Smith A, Cranfield T, et al. Acquired C1 esterase inhibitor deficiency or serendipity? the chance finding of a paraprotein after an apparently low C1 esterase inhibitor concentration. J Clin Pathol. 2004;57:445-447.
40. Gelfand JA, Boss GR, Conley CL, et al. Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore). 1979;58:321-328.
41. Donaldson VH, Hess EV, McAdams AJ. Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic edema. Ann Intern Med. 1977;86:312-313.
42. Farkas H, Szongoth M, Bely M, et al. Angioedema due to acquired deficiency of C1-esterase inhibitor associated with leukocytoclastic vasculitis. Acta Derm Venereol. 2001;81:298-300.
43. Donaldson VH, Bernstein DI, Wagner CJ, et al. Angioneurotic edema with acquired C1-inhibitor deficiency and autoantibody to C1-inhibitor: response to plasmapheresis and cytotoxic therapy. J Lab Clin Med. 1992;119:397-406.
44. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: primary structure cDNA cloning and chromosomal localization. Biochemistry. 1986;25:4292-4301.
45. Davis AE, Bissler JJ, Cicardi M. Mutations in the C1 inhibitor gene that result in hereditary angioneurotic edema. Behring Inst Mitt. 1993;93:313-320.
46. Ocejo-Vinyals JG, Leyva-Cobián F, Fernández-Luna JL. A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema. Mol Med. 1995;1:700-705.
47. Bissler JJ, Aulak KS, Donaldson VH, et al. Molecular defects in hereditary angioneurotic edema. Proc Assoc Am Physicians. 1997;109:164-173.
48. Zuraw BL, Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol. 2000;105:541-546.
49. Roche O, Blanch A, Duponchel C, et al. Hereditary angioedema: the mutation spectrum of SERPING1/C1NH in a large Spanish cohort. Hum Mutat. 2005;26:135-144.
50. Ratnoff OD, Lepow IH. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med. 1957;106:327-343.
51. Curd JG, Prograis JLJ, Cochrane CG. Detection of active kallinrein in induced blister fluids of hereditary angioedema patients. J Exp Med. 1980;152:742-747.
52. Curd JG, Yelvington M, Burridge NP, et al. Generation of bradykinin during incubation of hereditary angioedema plasma [abstract]. Mol Immunol. 1982;19:1365.
53. Fields T, Ghebrewihet B, Kaplan A. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of spontaneous formation of bradykinin. J Allergy Clin Immunol. 1983;72:54-60.
54. Shoemaker LR, Schurman SJ, Donaldson VH, et al. Hereditary angioneurotic edema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol. 1994;95:22-28.
55. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angiooedema. Lancet. 1998;351:1693-1697.
56. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109:1057-1063.
57. Davis AE. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114:3-9.
58. Nilsson T, Back O. Elevated plasmin-alpha 2-antiplasmin complex levels in hereditary angioedema: evidence for the in vivo efficiency of the intrinsic fibrinolytic system. Thromb Res. 1985;40:817-821.
59. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol. 1994;93:870-876.
60. Cugno M, Hack CE, de Boer JP, et al. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med. 1993;1121:38-43.
61. Spaulding WB. Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med. 1960;53:739-745.
62. Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol. N Engl J Med. 1976;295:1444-1448.
63. Bork K, Pitton M, Harten P, et al. Hepatocellular adenomas in patients taking danazol for hereditary angioedema. Lancet. 1999;353:1066-1067.
64. Frank MM, Sergent JS, Kane M, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med. 1972;286:808-812.
65. Waytes AT, Rosen RS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334:1630-1634.